Simulating the impact of a menthol BAN in the US; translating the canadian model
Ended Project Grant Awarded Last action
- Award ID
- R21CA260823
- Recipient
-
Centre For Addiction And Mental Health UEI YHQGDQJ58Q17
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $164,681
Award facts
- Assistance listing
- 93.077 Family Smoking Prevention and Tobacco Control Act Regulatory Research
- Completion date
- Originally
- Funding agency
- Office of the Director National Institutes of Health, Department of Health and Human Services
- Place of performance
- 2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Award details come from USAspending.gov.
Description
- Abstract
- Menthol cigarettes comprise a substantial portion of the american cigarette market with prevalence estimates reaching about 35% (FTC, 2016). Menthol is a flavouring agent added to cigarettes that masks the taste of tobacco, induces sensory effects, and recruits and retains smokers. After a thorough literature review, a U.S. Food and drug administration (FDA) advisory committee noted that banning menthol cigarettes would benefit public health and announced intentions to regulate the sale of menthol in tobacco in november 2019. However, in order to regulate menthol cigarettes, the FDA requires evidence on the expected impact of regulating menthol and real world knowledge on the process of implementation. This study will use two NIH/TRS funded longitudinal studies, the path in the US, and a cohort of smokers from ontario, canada to develop a simulation model predicting how the canadian BAN, one of the only evaluated national level implemented menthol BAN in the world, would be reflected in the US given differences in age, SEX, race, menthol use, and expectations of change of behaviour. The goal of this project is to estimates of the impact of the canadian menthol BAN to predict the impact of menthol regulations in the US on smoking cessation, health outcomes, and health costs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$37,930 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $202,611 | |
| Amendment | $202,611 | |
| Amendment | -$202,611 | |
| Amendment | -$202,611 | |
| Original award | $202,611 |
Quick answers
Who received award R21CA260823?
R21CA260823 was awarded to Centre For Addiction And Mental Health by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is award R21CA260823 worth?
$164,681 has been obligated on R21CA260823.
Which agency awarded R21CA260823?
National Cancer Institute (National Institutes of Health) awarded R21CA260823, with funding from Office of the Director (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award